📰 Randomized Study News
Page 4 - Randomized Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Randomized Study. Real-time updates on events, politics, business and more.
June 7, 2022
Scemblix® (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif®* (bosutinib) at 96...
June 7, 2022
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial
June 7, 2022
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif* (bosutinib) at 96 weeks (37.6% vs. 15.8%), building on 24-week
June 4, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
June 4, 2022
MAU868, a first-in-class monoclonal antibody, was well tolerated in kidney transplant recipients with BK viremiaData presented as oral late breaker at...
June 1, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
May 20, 2022
The registration number provided by the author for the Chinese Clinical Trial Registry (ChiCTR-IOR-17014122) seems to correspond to a different trial than the one described in the article.
May 19, 2022
New post-hoc data accepted as late breaking abstracts at the 90th European Atherosclerosis Society (EAS) Congress and 2022 National Lipid Association (NLA) Scientific Sessions NewAmsterdam Pharma
March 16, 2022
Clinically meaningful results with Mazindol ER exhibiting a 39% reduction in ESS from baseline (-4.3 points placebo-adjusted); confirms statistical powering of the ongoing Phase 2a trialSafety and tolerability
March 11, 2022
Certain nutrients are required for the female body to function effectively. Here are the 7 best multivitamins for women's health 2023. Find out which one is ideal for you.